Bilirubin Direct

High direct (conjugated) bilirubin indicates the liver isn’t properly excreting bilirubin or bile flow is obstructed. Causes include bile duct stones, strictures, tumors, cholestatic liver disease, or drug-induced cholestasis. Symptoms: jaundice, dark urine, pale stools, itchiness, abdominal pain and fatigue. Further evaluation (blood tests, liver imaging, sometimes ERCP) is needed and treatment targets the underlying cause.

In adults, total bilirubin above about 3 mg/dL usually causes visible jaundice; levels of 5–10 mg/dL indicate significant liver dysfunction and warrant urgent evaluation. Very high adult values (around or above 20 mg/dL) are dangerous. In newborns, bilirubin levels above about 20–25 mg/dL are considered high risk for brain injury (kernicterus) and require immediate medical treatment.

Reduce direct (conjugated) bilirubin by treating the underlying cause: relieve biliary obstruction (endoscopic/surgical removal of stones or stents), treat liver infections or autoimmune disease, stop hepatotoxic drugs, and manage sepsis. Medications for cholestasis (e.g., ursodeoxycholic acid) may help when indicated. Supportive care—hydration, nutrition, alcohol avoidance, weight control—and prompt specialist evaluation with imaging and labs are essential.

0.40 mg/dL direct (conjugated) bilirubin is mildly above the common laboratory cutoff (~0.3 mg/dL) and represents a slight elevation. Causes include cholestasis, hepatic inflammation, biliary obstruction or lab variability. Repeat testing and assessment of total bilirubin and liver enzymes (ALT/AST/ALP/GGT) are reasonable. See a clinician promptly if you have jaundice, dark urine, pale stools, or abdominal pain.

High direct (conjugated) bilirubin is treated by addressing the underlying cause: relieving biliary obstruction (ERCP, stent, surgery), treating infections or autoimmune liver disease (antibiotics/antivirals, immunosuppression), stopping hepatotoxic drugs, and using cholestasis therapies (ursodeoxycholic acid). Supportive care and monitoring are provided; severe liver failure may require transplantation. Phototherapy is generally ineffective for conjugated jaundice.

Fatty liver (NAFLD) usually does not cause significant bilirubin elevation; mild fatty infiltration raises ALT/AST, while bilirubin typically stays normal. However, if fatty liver progresses to steatohepatitis or cirrhosis it can impair bilirubin processing and lead to jaundice. Other causes (hemolysis, bile duct obstruction, medications) also raise bilirubin. See a clinician if bilirubin is high.